ITGAX and neoplasm: Given results from human samples [27–29], addition of antibodies for CD11c and CD123 (markers for conventional and plasmacytoid dendritic cells) and/or Siglec-8 (a marker for eosinophil) would enable more detailed discrimination of tumor infiltrating myeloid cells.